Current treatments involve intranasal corticosteroids, short-term systemic corticosteroids for symptom exacerbations, and surgical removal of nasal polyps. Type 2 inflammation is driven by ...

What you may think are allergies or a cold, could be the sign of nasal polyps. Nasal polyps are non-cancerous growths that line the nasal passages and sinuses. They are soft, painless, and hang ...

Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala is ...

Researchers have developed and preliminarily tested a composite score that simultaneously assesses the severity of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with both ...

The need for systemic corticosteroids fell by 88%, and the need for surgery fell by 98%. Nasal polyp and congestion scores fell, along with loss of smell and total symptom scores. SAN DIEGO ...

In this randomized controlled trial, among patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, tezepelumab more effectively reduced nasal polyp size and sinonasal symptoms ...

Chronic sinusitis with nasal polyps (CRSwNP) accounts for 20 to 33 percent of these cases. Even after surgical treatment, the recurrence rate of CRSwNP remains high, ranging from 20 to 60 percent ...

During the follow-up, 15.9% of patients required at least one revision surgery. The probability of revision sinus surgery ...

Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps.

Tezepelumab is an epithelial cytokine blocker used to treat severe asthma; its efficacy and safety in patients with chronic rhinosinusitis with nasal polyps have been unclear. New research ...